FOLFOX/bevacizumab plus /- irinotecan in advanced colorectal cancer (CHARTA): Long term outcome

被引：0
|
作者：
Schmoll, H. [1 ]
Garlipp, B. [2 ]
Junghanss, C. [3 ]
Vogel, A. [4 ]
Kaiser, U. [5 ]
Florschuetz, A. [6 ]
Kanzler, S. [7 ]
Hannig, C.
Meinert, F. [1 ]
Cygon, F. [1 ]
Stein, A. [8 ]
机构：
[1] Martin Luther Univ Halle Wittenberg, Halle, Germany
[2] Uniklin Magdeburg, Magdeburg, Germany
[3] Univ Rostock, Rostock, Germany
[4] Hannover Med Sch, Hannover, Germany
[5] Bernward Krankenhaus, Hildesheim, Germany
[6] Stadtisches Klinikum Dessau, Dessau, Germany
[7] Leopoldina Krankenhaus Schweinfurt, Med Klin 2, Schweinfurt, Germany
[8] Univ Med Ctr Hamburg, Hamburg, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O - 023
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [11] Impact of Early Tumour Shrinkage on Long-term Outcome In Metastatic Colorectal Cancer (mCRC) Treated With 5FU+Irinotecan plus Leucovorin (FOLFIRI) or Capecitabine plus Irinotecan XELIRI Plus Bevacizumab
    Ichante, J. L.
    Adenis, A.
    Francois, E.
    Boucher, E.
    Pignon, J. P.
    Ychou, M.
    Pierga, J. Y.
    Montotot-Grillo, C.
    Conroy, T.
    Ducreux, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S419 - S419
  • [12] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H
    Fehrenbacher, L
    Novotny, W
    Cartwright, T
    Hainsworth, J
    Heim, W
    Berlin, J
    Baron, A
    Griffing, S
    Holmgren, E
    Ferrara, N
    Fyfe, G
    Rogers, B
    Ross, R
    Kabbinavar, F
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23): : 2335 - 2342
  • [13] Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab.
    Ichante, J.
    Adenis, A.
    Malka, D.
    Francois, E.
    Boucher, E.
    Chauffert, B.
    Pignon, J.
    Ychou, M.
    Pierga, J.
    Montoto-Grillot, C.
    Conroy, T.
    Ducreux, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [14] Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer
    Ardavanis, A.
    Kountourakis, P.
    Mantzaris, I.
    Malliou, S.
    Doufexis, D.
    Sykoutri, D.
    Thomopoulos, M.
    Fragos, I.
    Rigatos, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [15] Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients
    Markus Moehler
    Martin F Sprinzl
    Murad Abdelfattah
    Carl C Schimanski
    Bernd Adami
    Werner Godderz
    Klaus Majer
    Dimitri Flieger
    Andreas Teufel
    Juergen Siebler
    Thomas Hoehler
    Peter R Galle
    Stephan Kanzler
    World Journal of Gastroenterology, 2009, 15 (04) : 449 - 456
  • [16] Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients
    Moehler, Markus
    Sprinzl, Martin F.
    Abdelfattah, Murad
    Schimanski, Carl C.
    Adami, Bernd
    Godderz, Werner
    Majer, Klaus
    Flieger, Dimitri
    Teufel, Andreas
    Siebler, Juergen
    Hoehler, Thomas
    Galle, Peter R.
    Kanzler, Stephan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (04) : 449 - 456
  • [17] A triple combination of Imatinib, Bevacizumab and Cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer
    Pessino, A.
    Andretta, V.
    Guglielmi, A.
    Mammoliti, S.
    Caprioni, F.
    Fornarini, G.
    Comandini, D.
    Sciallero, S.
    Ansaldi, F.
    Sobrero, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 344 - 344
  • [18] A phase III study of comparing FOLFOX plus /-bevacizumab with FOLFOX plus /-bevacizumab plus high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.
    Wang, Feng
    Xiao, Jian
    Zhang, Yan-Qiao
    Yuan, Xianglin
    Fang, Weijia
    Wang, Wei
    Hu, Xiaohua
    Zhuang, Zhixiang
    Zhou, Fuxiang
    Ying, Jieer
    Yuan, Ying
    Guo, Zeng-qing
    Wu, XiangYuan
    Zou, Qing-Feng
    He, Ming-ming
    Guo, Ying
    Chen, Shuang-Zhen
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [19] Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
    Bond, M. J. G.
    van Smeden, M.
    Degeling, K.
    Cremolini, C.
    Schmoll, H. J. E-V.
    Rossini, D.
    Ibach, S.
    Koopman, M.
    Punt, C. J. A.
    May, A. M.
    Kwakman, J. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S438 - S438
  • [20] UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer
    Price, T
    Hill, M
    ONCOLOGY-NEW YORK, 2000, 14 (10): : 28 - 31
12345